{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T14:03:39Z","timestamp":1764079419342,"version":"3.37.3"},"reference-count":19,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2018,11,14]],"date-time":"2018-11-14T00:00:00Z","timestamp":1542153600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100000038","name":"U.S. Food and Drug Administration","doi-asserted-by":"publisher","award":["HHSF223200910006I"],"award-info":[{"award-number":["HHSF223200910006I"]}],"id":[{"id":"10.13039\/100000038","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacoepidemiology and Drug"],"published-print":{"date-parts":[[2019,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Purpose<\/jats:title><jats:p>To describe the use of tumor necrosis factor\u2010alpha inhibitors (TNFis) among pregnancies ending in a live birth and with a diagnosis of ankylosing spondylitis (AS), Crohn's disease (CD), juvenile idiopathic arthritis (JIA), psoriasis (PsO), psoriatic arthritis (PsA), rheumatoid arthritis (RA), or ulcerative colitis (UC).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We identified pregnancies among women aged 15 to 54\u00a0years between 01\/01\/2004 and 09\/30\/2015 from 16 health plans participating in Sentinel. We inferred indication using ICD\u20109\u2010CM codes in the 183\u2010day period before conception. We assessed proportion of infliximab, etanercept, adalimumab, certolizumab pegol, and golimumab by calendar year, indication, and maternal age, and compared them to proportions in an age\u2010matched, indication\u2010matched, and date\u2010matched non\u2010pregnant cohort.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Among 19\u00a0681 pregnancies with at least one chronic inflammatory condition, 2990 (15.2%) received a TNFi. In both pregnancies and matched non\u2010pregnant cohort, TNFi use was highest (34.4%; 55.8%) for PsA patients and lowest (6.2%; 13.4%) for PsO patients. Etanercept was most frequently used among AS\/JIA\/PsA\/PsO\/RA patients, while infliximab was the preferred TNFi for CD\/UC patients. Except for infliximab and certolizumab, TNFi use during pregnancy decreased after the first trimester. Pregnancies among older pregnant women (45\u201054\u00a0years) were more likely to be treated compared with the matched non\u2010pregnant cohort.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>There was a preference for etanercept among pregnancies with AS\/JIA\/PsA\/PsO\/RA, despite the availability of other TNFis. Decline in TNFi use after the first trimester may be related to the desire to reduce TNFis transplacental transfer and to minimize infection risk to the fetus or baby associated with live vaccine immunizations after birth.<\/jats:p><\/jats:sec>","DOI":"10.1002\/pds.4695","type":"journal-article","created":{"date-parts":[[2018,11,15]],"date-time":"2018-11-15T10:30:55Z","timestamp":1542277855000},"page":"296-304","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Use of tumor necrosis factor\u2010alpha inhibitors during pregnancy among women who delivered live born infants"],"prefix":"10.1002","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8971-9748","authenticated-orcid":false,"given":"Efe","family":"Eworuke","sequence":"first","affiliation":[{"name":"Division of Epidemiology II, Office of Pharmacovigilance and Epidemiology, Office of Surveillance and Epidemiology Center for Drug Evaluation and Research, Food and Drug Administration  Silver Spring MD USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Genna","family":"Panucci","sequence":"additional","affiliation":[{"name":"Department of Population Medicine Harvard Pilgrim Health Care Institute  Boston MA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Margie","family":"Goulding","sequence":"additional","affiliation":[{"name":"Division of Epidemiology II, Office of Pharmacovigilance and Epidemiology, Office of Surveillance and Epidemiology Center for Drug Evaluation and Research, Food and Drug Administration  Silver Spring MD USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rosemarie","family":"Neuner","sequence":"additional","affiliation":[{"name":"Division of Pulmonary, Allergy and Rheumatology Products, Office of New Drugs Center for Drug Evaluation and Research, Food and Drug Administration  Silver Spring MD USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5160-0810","authenticated-orcid":false,"given":"Sengwee","family":"Toh","sequence":"additional","affiliation":[{"name":"Department of Population Medicine Harvard Pilgrim Health Care Institute  Boston MA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2018,11,14]]},"reference":[{"issue":"11","key":"e_1_2_10_2_1","first-page":"704","article-title":"Update on the incidence and prevalence of inflammatory bowel disease in the United States","volume":"12","author":"Loftus EV","year":"2016","journal-title":"Gastroenterol Hepatol"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1196\/annals.1351.019"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2012.339"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-319-19530-8_4"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/bdra.23033"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2012.11.011"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.105924"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(17)34376-7"},{"issue":"1","key":"e_1_2_10_10_1","first-page":"1","article-title":"The U.S. Food and Drug Administration's Mini\u2010Sentinel program: status and direction","volume":"21","author":"Platt R","year":"2012","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.2336"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.3407"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10995-015-1878-8"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.2319"},{"key":"e_1_2_10_15_1","unstructured":"Organization of Teratology Information Specialists. Etanercept (Enbrel).Mother to baby: medications and more during pregnancy and breastfeeding ask the experts;2015. Available athttps:\/\/mothertobaby.org\/fact\u2010sheets\/etanercept\u2010enbrel\u2010pregnancy\/pdf\/. Accessed 10\/4\/2017 2017."},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2003.016881"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0897.1992.tb00801.x"},{"key":"e_1_2_10_18_1","unstructured":"AdrienneB.Why are 50 percent of pregnancies in the U.S. unplanned?2013. Available athttp:\/\/shriverreport.org\/why\u2010are\u201050\u2010percent\u2010of\u2010pregnancies\u2010in\u2010the\u2010us\u2010unplanned\u2010adrienne\u2010d\u2010bonham\/. Accessed 10\/3\/2017."},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1097\/MIB.0000000000001102"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2013.10.047"}],"container-title":["Pharmacoepidemiology and Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fpds.4695","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pds.4695","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,14]],"date-time":"2023-09-14T02:12:50Z","timestamp":1694657570000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pds.4695"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,14]]},"references-count":19,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,3]]}},"alternative-id":["10.1002\/pds.4695"],"URL":"https:\/\/doi.org\/10.1002\/pds.4695","archive":["Portico"],"relation":{},"ISSN":["1053-8569","1099-1557"],"issn-type":[{"type":"print","value":"1053-8569"},{"type":"electronic","value":"1099-1557"}],"subject":[],"published":{"date-parts":[[2018,11,14]]},"assertion":[{"value":"2017-12-11","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-10-10","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-11-14","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}